{
  "id": 219288,
  "title": "The chink in Europe’s innovation armour",
  "url": "https://urgent.news/2026/08/06/the-chink-in-europes-innovation-armour",
  "topic": "business",
  "section": "Business",
  "published": "2026-08-06T12:01:45.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/08/the-chink-in-europes-innovation-armour/"
  },
  "original_language": "en",
  "account": "Europe's reputation has long been that of a hub for innovation, driven by substantial research and development spending and a robust pipeline of university spin-offs. In 2024, the EU invested €403 billion in R&D, employing 2.21 million researchers – a 47% increase from a decade earlier. Despite this, European innovation still lags behind the US, Japan, and South Korea, as R&D spending represents only 2.24% of EU GDP. While European research institutions produced around 100 DeepTech and life-science spin-offs annually between 2000 and 2010, since 2015, this number has surged to over 500 annually, with more than 7,300 companies now employing 167,000 individuals and boasting a combined valuation of €344 billion.\n\nHowever, the challenge lies in translating scientific breakthroughs into commercially viable products. Venture capital funding attracts DeepTech companies, but only 23% of EU university spin-offs operate in this sector compared to 60% in the US. The issue becomes even more pronounced when the research transitions from the lab to the market. Only 86% of early-stage capital raised by European DeepTech and life-science spin-offs remains within the continent, with the rest coming from outside, mainly the US. Since 2019, American companies and investors have reaped close to €20 billion worth of value from European spin-offs, even as research output has grown exponentially.\n\nThe funding landscape for European research spin-offs presents a unique set of challenges. The EIC Accelerator and Transition scheme offer support for technologies at specific research levels, but these programs do not always accommodate the early-stage nature of university spin-offs. Commercialization often requires navigating intellectual property, demonstrating technology effectiveness beyond the lab, and building a company before revenue becomes realistic. European technology-transfer offices show a lower licensing income compared to their US counterparts, partly due to a lack of industry experience within these offices.",
  "summary": "Europe’s strength arguably has been, and still is, innovation. However, there are other contenders on the block, and their ability to commercialise that research is attracting European-bred talent to different shores. Europe spent €403 billion on research and development in 2024. It employed 2.21 million full-time-equivalent researchers, 47% more than a decade earlier. These are […] The post The…",
  "key_points": [
    "Europe invests €403 billion in R&D in 2024, employing 2.21 million researchers.",
    "European innovation lags behind US, Japan, South Korea with R&D representing only 2.24% of EU GDP."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}